- Updated analysis from ongoing phase 1 study of DS-8201 demonstrated a confirmed overall response rate of 45.5 percent and a disease control rate of 81.8 percent in 44 evaluable patients with HER2-expressing gastric cancer previously treated with trastuzumab and chemotherapy - Prelimi...
from PR Newswire: //www.prnewswire.co.uk/news-releases/daiichi-sankyo-presents-updated-data-for-ds-8201-in-patients-with-her2-expressing-gastric-cancer-at-asco-2018-gastrointestinal-cancers-symposium-669910813.html
No comments:
Post a Comment